{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:30:32Z","timestamp":1774312232468,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"vor","delay-in-days":731,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cysticfibrosisjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jcf.2014.11.005","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T06:35:53Z","timestamp":1418279753000},"page":"370-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9811-8004","authenticated-orcid":false,"given":"Elliott C.","family":"Dasenbrook","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Konstan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald R.","family":"VanDevanter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2014.11.005_bb0005","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment of lung infection in patients with cystic fibrosis: current and future strategies","volume":"11","author":"Doring","year":"2012","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2014.11.005_bb0010","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2014.11.005_bb0015","series-title":"2009 annual data report to the center directors","author":"Cystic Fibrosis Foundation Patient Registry","year":"2010"},{"key":"10.1016\/j.jcf.2014.11.005_bb0020","series-title":"2012 annual data report to the center directors","author":"Cystic Fibrosis Foundation Patient Registry","year":"2013"},{"key":"10.1016\/j.jcf.2014.11.005_bb0025","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/S1569-1993(14)60051-5","article-title":"Incorporation of a third inhaled antipseudomonal antibiotic class into the management of patients at an adult CF care center","volume":"13","author":"VanDevanter","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2014.11.005_bb0030","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ppul.1950150204","article-title":"Pulmonary function between 6 and 18years of age","volume":"15","author":"Wang","year":"1993","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2014.11.005_bb0035","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.jcf.2014.11.005_bb0040","doi-asserted-by":"publisher","first-page":"e101717","DOI":"10.1371\/journal.pone.0101717","article-title":"eulerAPE: Drawing area-proportional 3-Venn diagrams using ellipses","volume":"9","author":"Micallef","year":"2014","journal-title":"PLoS ONE"},{"issue":"Suppl. 2","key":"10.1016\/j.jcf.2014.11.005_bb0045","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/S0954-6111(11)70023-3","article-title":"Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis","volume":"105","author":"VanDevanter","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2014.11.005_bb0050","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/ppul.20873","article-title":"Shifting patterns of inhaled antibiotic use in cystic fibrosis","volume":"43","author":"Moskowitz","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2014.11.005_bb0055","series-title":"Clinicaltrials.Gov [internet]. Bethesda (md): National library of medicine (us)","article-title":"Phase 3 study of aztreonam for inhalation solution (AZLI) in a continuous alternating therapy regimen for the treatment of chronic Pseudomonas aeruginosa infection in patients with CF (AZLI CAT)","author":"Bresnik","year":"2012"},{"issue":"2","key":"10.1016\/j.jcf.2014.11.005_bb0060","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4155\/cli.11.174","article-title":"Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease","volume":"2","author":"VanDevanter","year":"2012","journal-title":"Clin Investig"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199314002665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199314002665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T22:56:01Z","timestamp":1538002561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199314002665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1569199314002665"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2014.11.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2014.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}